Enko and Syngenta take a machine-learned fungicide into a second field season
Enko Chem and Syngenta completed a first field season on three continents for a fungicide hitting a new target. A second season is planned.
Enko Chem said on 19 November that a fungicide chemistry discovered on its ENKOMPASS platform survived its first full season of field testing and will go into a second one. Syngenta Crop Protection ran the trials, evaluating the compound against leading products under a range of growing conditions in Europe, North America and Asia. According to the companies, the disease control first seen in the greenhouse carried over to field conditions.
The compound acts on a biological target that, in the words of Enko chief executive Tony Klemm, "Fungicide researchers have pursued this target for decades." He added that "ENKOMPASS delivered chemistry that acts on a new target, and a full season in the field provides further confirmation." Neither company is releasing the underlying field data, which is normal while a molecule is still in development, and neither has named the target, the chemical class or a lead crop. AgNavigator, reporting the same day, put the work on fungal pathogens in cereals.
Enko Chem was founded in 2017 and is based in Mystic, Connecticut. ENKOMPASS screens large molecule libraries computationally to find previously unexplored biological targets, the aim being to reach modes of action that conventional discovery programmes have missed. The company's backers include the Gates Foundation, Anterra Capital, DYDX Capital, Novalis LifeSciences, Germin8 Ventures, TO Ventures Food and the Rabo Food & Agri Innovation Fund. No financial terms of the Syngenta collaboration have been disclosed.
The commercial logic sits in the cost of the alternative. Klemm told AgNavigator that carrying a new mode of action from discovery through regulatory approval to a finished product typically runs to about 300 million dollars and 13 to 14 years, and that Enko is targeting a 75 per cent cut in discovery time at roughly a tenth of the usual cost. The two companies have worked together since 2021, and the discovery behind this chemistry was first disclosed in January 2024. A second season will inform whether Syngenta takes the chemistry further.
For founders building discovery platforms, the useful detail here is what counts as proof. Enko has not published efficacy numbers and does not need to: the validating event is that a major crop protection company put the molecule into its own multi-continent trial network and then committed another season of its scarce plot capacity. That decision, not a press release figure, is what a Series B investor will look at. The lesson for platform companies in biologicals, crop protection and seed traits is to structure the incumbent relationship early so that each season produces an auditable go or no-go, because a platform with no partner-funded field data is still a thesis after five years of compute.
Enko and Syngenta take a machine-learned fungicide into a second field season
A compound from Enko's ENKOMPASS platform held its disease control through a first full season of trials on three continents, and Syngenta Crop Protection will run a second season.
Enko Chem said on 19 November that a fungicide chemistry discovered on its ENKOMPASS platform survived its first full season of field testing and will go into a second one. Syngenta Crop Protection ran the trials, evaluating the compound against leading products under a range of growing conditions in Europe, North America and Asia. According to the companies, the disease control first seen in the greenhouse carried over to field conditions.
The compound acts on a biological target that, in the words of Enko chief executive Tony Klemm, "Fungicide researchers have pursued this target for decades." He added that "ENKOMPASS delivered chemistry that acts on a new target, and a full season in the field provides further confirmation." Neither company is releasing the underlying field data, which is normal while a molecule is still in development, and neither has named the target, the chemical class or a lead crop. AgNavigator, reporting the same day, put the work on fungal pathogens in cereals.
Enko Chem was founded in 2017 and is based in Mystic, Connecticut. ENKOMPASS screens large molecule libraries computationally to find previously unexplored biological targets, the aim being to reach modes of action that conventional discovery programmes have missed. The company's backers include the Gates Foundation, Anterra Capital, DYDX Capital, Novalis LifeSciences, Germin8 Ventures, TO Ventures Food and the Rabo Food & Agri Innovation Fund. No financial terms of the Syngenta collaboration have been disclosed.
The commercial logic sits in the cost of the alternative. Klemm told AgNavigator that carrying a new mode of action from discovery through regulatory approval to a finished product typically runs to about 300 million dollars and 13 to 14 years, and that Enko is targeting a 75 per cent cut in discovery time at roughly a tenth of the usual cost. The two companies have worked together since 2021, and the discovery behind this chemistry was first disclosed in January 2024. A second season will inform whether Syngenta takes the chemistry further.
For founders building discovery platforms, the useful detail here is what counts as proof. Enko has not published efficacy numbers and does not need to: the validating event is that a major crop protection company put the molecule into its own multi-continent trial network and then committed another season of its scarce plot capacity. That decision, not a press release figure, is what a Series B investor will look at. The lesson for platform companies in biologicals, crop protection and seed traits is to structure the incumbent relationship early so that each season produces an auditable go or no-go, because a platform with no partner-funded field data is still a thesis after five years of compute.